Clinical Applications of Integrative Analysis of Validated Somatic and Germline Genomic Results in Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 25 April 2025 | Viewed by 1111
Special Issue Editor
Special Issue Information
Dear Colleagues,
The aim of this Special Issue is to give a platform to studies that utilize and demonstrate the value of an integrated approach combining validated somatic (tumor) and germline (constitutional) genomic data for clinical management of cancer and precision oncology. Somatic and germline analysis has been reported to be beneficial in personalized therapeutic practice, tumorigenesis and cancer progression, inference on germline allele penetrance, and gene discovery. However, clinical applications of the integration of somatic and germline data are not routinely published. Signature somatic genomic profiles such as loss of heterozygosity (LOH), mismatch repair (MMR) status (i.e., MMR deficient or proficient), microsatellite instability (MSI), and tumor-derived information such as immunohistochemistry (IHC) of target proteins have unique values that can shed light on the role of germline genetic variants in disease. The understanding of genome findings from the somatic workflow can be much enhanced when performed in the context of patients’ constitutional genetic data. Conversely, the full extent of the consequence of germline findings, both in cancer susceptibility and therapy, can be elucidated when examined with somatic genetic data in unison.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Special Issue.
Dr. Arezou A. Ghazani
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor and constitutional genome integration
- clinical application of somatic and germline findings
- precision oncology
